Thyroid Cancer

Thyroid cancer is increasing in incidence due to better detection rate and is currently the most common endocrine cancer. It has an incidence rate of 9:100 000. There are 5 main subtypes of thyroid cancer, two of which make up around 90% of cases and have an excellent prognosis – the survival rate is over 95% twenty years following diagnosis. Thyroid cancers usually present with a painless lump in the neck, either in the thyroid gland or in a lymph node. Very rarely they can present with pain, a hoarse voice or problems swallowing. Any thyroid cancer or patients with a suspicion of thyroid cancer should be discussed at a thyroid multidisciplinary team (MDT) meeting of cancer specialists. Robert Hone and Ali Al-Lami are both members of the East Kent thyroid and parathyroid MDT.
Papillary thyroid cancer is the most common thyroid cancer accounting for around 70% of all thyroid cancer. Papillary thyroid cancer is usually “well differentiated” which means it resembles the tissue that it arises from and grows slowly and does not behave in an aggressive way, remaining stable in size. These have an excellent prognosis with survival of over 95% at twenty years. Occasionally, they are poorly differentiated – they grow much faster, are more aggressive and unfortunately have a worse prognosis. If papillary thyroid cancer spreads, it is usually to the lymph nodes in the neck and these can be treated relatively easily.
Follicular thyroid cancer is the second most common thyroid cancer and makes up around 20% of all thyroid cancers. Prognosis is also excellent at over 95% at 20 years. However this cancer tends to spread through the blood stream meaning cancer deposits at distant sites are more common and if this happens, follicular thyroid cancer is harder to treat. Depending on the treatment you receive a blood marker called thyroglobulin can be used to monitor papillary thyroid cancer.
Medullary thyroid cancer is rare and makes up around 5% of all thyroid cancer. It can have a genetic disposition and patients with this form of cancer are screened for genetic changes that may make them more susceptible to this type of thyroid cancer or more likely to develop tumours in other areas of the body. Medullary thyroid cancer can be monitored after treatment using a blood tumour marker called calcitonin (a chemical in the blood produced by medullary thyroid cancer).
Lymphoma of the thyroid gland also accounts for around 5% of thyroid cancers. It usually grows quite quickly and responds very well to treatment. Once diagnosed you will be referred to the lymphoma multidisciplinary team meeting and your care taken over by the Haematology Department for treatment, which is usually chemotherapy and/or radiotherapy.
Anaplastic thyroid cancer is rare and makes up less than 1% of all thyroid cancer. Unfortunately, this cancer is very aggressive, and prognosis is very poor. It grows very quickly – invading other structures and sends cancer deposits to other areas of the body meaning surgery is often not possible and chemotherapy and radiotherapy rarely have any effect on this cancer. Sadly, less than 10% of people survive more than a year following the diagnosis, which can be difficult to obtain.
The best treatment for thyroid cancer is surgery to remove the tumour. Depending on the individual risk factors, the type, stage and size of the cancer, additional treatment may be offered. This can be in the form or radioactive iodine treatment and in rare instances radiotherapy with or without chemotherapy. Systemic chemotherapy has a limited role in thyroid cancer and is only occasionally used in specific cases. A regular blood test to look for a blood marker called thyroglobulin and antibodies called thyroglobulin antibodies may also be indicated to look for the presence of any remaining thyroid tissue. If these markers are increasing it may suggest the presence of residual or recurrence of your thyroid cancer and further investigations or treatment may be indicated.